@article{b4a1beb6534a4a7ab886823573583d3e,
title = "Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper",
abstract = "This Review provides an updated approach to the diagnosis of idiopathic pulmonary fibrosis (IPF), based on a systematic search of the medical literature and the expert opinion of members of the Fleischner Society. A checklist is provided for the clinical evaluation of patients with suspected usual interstitial pneumonia (UIP). The role of CT is expanded to permit diagnosis of IPF without surgical lung biopsy in select cases when CT shows a probable UIP pattern. Additional investigations, including surgical lung biopsy, should be considered in patients with either clinical or CT findings that are indeterminate for IPF. A multidisciplinary approach is particularly important when deciding to perform additional diagnostic assessments, integrating biopsy results with clinical and CT features, and establishing a working diagnosis of IPF if lung tissue is not available. A working diagnosis of IPF should be reviewed at regular intervals since the diagnosis might change. Criteria are presented to establish confident and working diagnoses of IPF.",
author = "Lynch, {David A.} and Nicola Sverzellati and Travis, {William D.} and Brown, {Kevin K.} and Colby, {Thomas V.} and Galvin, {Jeffrey R.} and Goldin, {Jonathan G.} and Hansell, {David M.} and Yoshikazu Inoue and Takeshi Johkoh and Nicholson, {Andrew G.} and Knight, {Shandra L.} and Suhail Raoof and Luca Richeldi and Ryerson, {Christopher J.} and Ryu, {Jay H.} and Wells, {Athol U.}",
note = "Funding Information: DMH reports personal fees from AstraZeneca, Sanofi, Boehringer Ingelheim, and Roche, outside the submitted work. YI reports personal fees from Boehringer Ingelheim and Asahi Kasei, and grants from the Japanese Ministry of Health Labour and Welfare, and Japan Agency for Medical Research and Development, outside the submitted work. DAL reports grants from the National Heart, Lung, and Blood Institute (NHLBI), and personal fees from PAREXEL, Veracyte, Boehringer Ingelheim, and Genentech, outside the submitted work. AGN reports personal fees from Boehringer Ingelheim, Sanofi, Med Quantitative Image Analysis, and Roche, outside the submitted work. LR reports grants and personal fees from Boehringer Ingelheim and InterMune, personal fees from MedImmune, and personal fees from Biogen Idec, Sanofi-Aventis, Roche, Takeda, ImmuneWorks, and Shionogi, outside the submitted work. CJR reports grants and personal fees from Boehringer Ingelheim and Hoffmann La Roche, outside the submitted work. NS reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. AUW reports personal fees from Intermune, Boehringer Ingelheim, Bayer, and Gilead, outside the submitted work. All other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",
year = "2018",
month = feb,
doi = "10.1016/S2213-2600(17)30433-2",
language = "English (US)",
volume = "6",
pages = "138--153",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "2",
}